Fiona M Behan
Fiona M Behan
Scientific Leader, GSK
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
FM Behan, F Iorio, G Picco, E Gonçalves, CM Beaver, G Migliardi, ...
Nature 568 (7753), 511-516, 2019
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency data sets
JM Dempster, C Pacini, S Pantel, FM Behan, T Green, J Krill-Burger, ...
Nature communications 10 (1), 1-14, 2019
Unsupervised correction of gene-independent cell responses to CRISPR-Cas9 targeting
F Iorio, FM Behan, E Gonçalves, SG Bhosle, E Chen, R Shepherd, ...
BMC genomics 19 (1), 1-16, 2018
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR-Cas9 screening
G Picco, ED Chen, LG Alonso, FM Behan, E Gonçalves, G Bignell, ...
Nature communications 10 (1), 1-12, 2019
JACKS: joint analysis of CRISPR/Cas9 knockout screens
F Allen, F Behan, A Khodak, F Iorio, K Yusa, M Garnett, L Parts
Genome research 29 (3), 464-471, 2019
An integrative genomic approach in oesophageal cells identifies TRB3 as a bile acid responsive gene, downregulated in Barrett's oesophagus, which regulates NF-κB activation and …
SP Duggan, FM Behan, M Kirca, S Smith, JV Reynolds, A Long, ...
Carcinogenesis 31 (5), 936-945, 2010
Structural rearrangements generate cell-specific, gene-independent CRISPR-Cas9 loss of fitness effects
E Gonçalves, FM Behan, S Louzada, D Arnol, EA Stronach, F Yang, ...
Genome biology 20 (1), 1-10, 2019
The characterization of an intestine-like genomic signature maintained during Barrett’s-associated adenocarcinogenesis reveals an NR5A2-mediated promotion of cancer cell survival
SP Duggan, FM Behan, M Kirca, A Zaheer, SA McGarrigle, JV Reynolds, ...
Scientific reports 6 (1), 1-16, 2016
Drug mechanism‐of‐action discovery through the integration of pharmacological and CRISPR screens
E Gonçalves, A Segura‐Cabrera, C Pacini, G Picco, FM Behan, P Jaaks, ...
Molecular systems biology 16 (7), e9405, 2020
siRNA library screening identifies a druggable immune-signature driving esophageal adenocarcinoma cell growth
SP Duggan, C Garry, FM Behan, S Phipps, H Kudo, M Kirca, A Zaheer, ...
Cellular and molecular gastroenterology and hepatology 5 (4), 569-590, 2018
Project Score database: a resource for investigating cancer cell dependencies and prioritizing therapeutic targets
L Dwane, FM Behan, E Gonçalves, H Lightfoot, W Yang, D van der Meer, ...
Nucleic Acids Research 49 (D1), D1365-D1372, 2021
Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening
FM Behan, F Iorio, E Gonçalves, G Picco, CM Beaver, R Santos, Y Rao, ...
bioRxiv, 502005, 2018
Genomics of Drug Sensitivity in Cancer (GDSC): A resource for biomarker discovery in cancer cells
W Yang, H Lightfoot, G Bignell, F Behan, T Cokelear, D Haber, ...
European Journal of Cancer 1 (69), S82, 2016
Minimal genome-wide human CRISPR-Cas9 library
E Gonçalves, M Thomas, FM Behan, G Picco, C Pacini, F Allen, A Vinceti, ...
Genome biology 22 (1), 1-14, 2021
Combinatorial CRISPR screen identifies fitness effects of gene paralogues
NA Thompson, M Ranzani, L van der Weyden, V Iyer, V Offord, A Droop, ...
Nature communications 12 (1), 1-11, 2021
Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway
AWY Chai, P San Yee, S Price, SM Yee, HM Lee, VKH Tiong, ...
eLife 9, e57761, 2020
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens nominates the Werner Syndrome RecQ helicase as a synthetic lethal target in MMR-deficient tumours
G Picco, FM Behan, F Iorio, E Goncalves, CM Beaver, G Migliardi, ...
Functional linkage of gene fusions to cancer cell fitness assessed by pharmacological and CRISPR/Cas9 screening
M Garnett, G Picco, E Chen, LG Alonso, F Behan, E Goncalves, G Bignell, ...
BioRxiv, 2019
SPOT-012 Large-scale CRISPR screening to identify actionable cancer drug targets
F Behan, F Iorio, E Stronach, C Beaver, RM Santos, J Saez-Rodriguez, ...
ESMO Open 3 (Suppl 2), 2018
34 Gene fusions in 1,015 human cancer cell lines: integrating large-scale genomic data, high-throughput drug and CRISPR/Cas9 screens to assess functional relevance and …
E Chen, G Picco, L Garcia-Alonso, G Bignell, F Behan, A Matchan, F Iorio, ...
ESMO Open 3 (Suppl 2), 2018
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20